News & blog

LISTED drug developer Redx Pharma has struck a deal with a fellow a Cheshire company to supply its Porcupine inhibitor – which tackles hard-to-treat cancers for clinical trials. Porcupine (RXC004) battles pancreative, triple negative breast and head and neck cancers. First in-human studies are expected to start early in 2017.

The deal is with Quay Pharma which will manufacture RXC004. The novel, potent small molecule Porcupine inhibitor targets the Wnt pathway, an embryonic signalling pathway implicated in the maintenance… Read more